58 results about "Hypercholesteraemia" patented technology

The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents such as small interfering RNA (siRNA) molecules, able to inhibit proprotein convertase subtilisin kexin 9 (PCSK9) gene expression. Also disclosed are pharmaceutical compositions that include PCSK9 RNAi agents and methods of use thereof. The PCSK9 RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosamine, to facilitate the delivery to hepatocyte cells. Delivery of the PCSK9 RNAi agents in vivo provides for in vivo provides for inhibition of PCSK9 gene expression and thereby reduction of PCSK9 protein. The RNAi agents can be used in methods of treatment of diseases or disorders mediated at least in part by PCSK9 gene expression, including among others hypercholesterolemia, familial hypercholesterolemia including heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH), familial hypobetalipoproteinemia, hyperlipidemia, coronary artery disease, polygenic dyslipidemia, heart disease, cardiovascular disease (CVD) including clinical atherosclerotic cardiovascular disease (ASCVD).

The present invention provides methods for treating patients suffering from familial hypercholesterolemia, including both HeFH and HoFH. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to ANGPTL3 in combination with a therapeutically effective amount of a statin, a first lipid lowering agent other than a statin, and a second lipid lowering agent other than a statin. The first non-statin lipid lowering agent is an agent that inhibits cholesterol uptake (e.g. ezetimibe) and the second non-statin lipid-lowering agent is an inhibitor of microsomal triglyceride transfer protein (e.g. lomitapide). The combination therapy is useful in treating hypercholesterolemia, as well as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, chylomicronemia, and to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor, such as cardiovascular diseases.

25HC3S choline and crystalline 25HC3S choline are described in the present application. Further disclosed herein are pharmaceutical formulations of 25HC3S choline (e.g., containing crystalline 25HC3S choline) and methods of using the pharmaceutical formulations to treat or prevent diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, atherosclerosis, hypercholesteremia, hypertriglyceridemia, and the like. Methods of treating fatty liver disease (AFLD), alcoholic steatohepatitis (ASH), leptin resistance, leptin deficiency, diabetic conditions, autoimmune conditions, inflammatory conditions, neurological conditions, Epstein-Barr virus associated growth, and conditions associated with fat accumulation and inflammation are provided. Also provided herein are methods of making 25HC3S, including crystalline 25HC3S choline.

The present invention relates to a combination of Chinese and Western medicines for treating hyperlipidemia. In particular, the present invention relates to a pharmaceutical combination of probucol and red yeast rice, a pharmaceutical composition or a kit comprising probucol and red yeast rice, and the use of the pharmaceutical combination, pharmaceutical composition or kit in preparing a medicament for treating hyperlipidemia, particularly severe hypertriglyceridemia and severe hypercholesterolemia. The present invention is characterized in that the pharmaceutical combination, pharmaceutical composition or kit comprising probucol and red yeast rice comprises a small dose of probucol and red yeast rice, and the probucol and red yeast rice are configured for simultaneous administration.

Compositions and method of increasing levels of apoA1 and / HDL in a subject in need thereof are provided. The compositions include one or more TLR5 agonists in a pharmaceutically acceptable carrier in an effective amount to increase the level of apoA1 and / or HDL in a subject. In a preferred embodiment, the composition is an oral formulation of the one or more TLR5 agonists. The disclosed methods include administering compositions containing the one or more TLR5 agonists to a subject in need thereof, in an effective amount to increase levels of apoA1 and / or HDL in the subject. In one preferred embodiment, the subject is at risk of developing atherosclerosis and / or coronary heart disease. In some embodiments, the subject is diagnosed as having atherosclerosis. The disclosed compositions can also be administered to subjects presenting with hyperlipidemia or hypercholesterolemia.

The present invention relates to use of a GLP-1R / GLP-2R dual agonist, namely dapiglutide, for reducing cholesterol, in particular total cholesterol (TC) and low-density lipoprotein cholesterol (LDL cholesterol). The invention also relates to dapiglutide for treatment of hyperlipidaemia, in particular hypercholesterolaemia.

The present invention relates to the technical field of liver-protecting formula compositions, and in particular, to a liver-protecting milk thistle formula composition, and a preparation method thereof. Technical problems: the liver-protecting milk thistle formula composition, and a preparation method thereof are intended to solve the technical problems that most of existing liver-protecting compositions in the prior art are designed for the general liver protection needs of the general population and cannot specifically treat liver damage caused by excessive alcohol intake and liver diseases such as cirrhosis, acute hepatitis, hepatitis, fatty liver, cholangitis, cholelithiasis, psoriasis, and hypercholesterolemia. Technical solution: a liver-protecting milk thistle formula composition, including the following components: silymarin, puerarin, artichoke extract, glutathione, dandelion extract, and GABA. The liver-protecting formula composition has a good therapeutic effect on liver damage caused by excessive alcohol intake, and liver diseases such as cirrhosis, acute hepatitis, hepatitis, fatty liver, cholangitis, cholelithiasis, psoriasis, and hypercholesterolemia.

The application relates to the field of biological medicine, in particular to application of TDF in serum cholesterol regulation and a verification method. The application discloses that tenofovir disoproxil fumarate (TDF) can inhibit intestinal cholesterol absorption by specifically down-regulating the expression level of NPC1L1 protein in the intestinal tract, so as to reduce serum cholesterol. The regulation has tissue specificity, and TDF has no significant influence on the expression of key genes of liver cholesterol metabolism. The application also provides a method for verifying the regulation of TDF on serum cholesterol, which is evaluated by detecting blood lipid indexes and the gene and / or protein expression level of NPC1L1 in duodenal tissue. The application provides a treatment scheme with antiviral and cholesterol-lowering effects for patients with chronic hepatitis B combined with hypercholesterolemia, and provides a new idea for developing a lipid-lowering strategy targeting intestinal cholesterol absorption.

The invention relates to the technical field of biological medicine. The invention provides a PCSK9-targeted PROTAC oral drug as well as a preparation method and application thereof. The drug comprises the following structures: a PCSK9 binding peptide, an E3 ubiquitin ligase ligand, a cell penetrating peptide and a flexible linker. The medicine provided by the invention can be used for preparing products for treating lipid metabolism disorder diseases such as hypercholesteremia and atherosclerosis. In addition, the medicine disclosed by the invention can also be combined with statins to synergistically enhance the lipid-lowering curative effect.

The disclosure provides methods of treating heterozygous familial hypercholesterolemia (HeFH) and / or atherosclerotic cardiovascular disease (ASCVD), more particularly in subjects who require additional lowering of low-density lipoprotein cholesterol (LDL-C). The method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising obicetrapib or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

The invention discloses a preparation method of torreya grandis gel candies with an effect of reducing total cholesterol. The invention belongs to the technical field of functional food, the Chinese torreya oil and the flaxseed oil have a synergistic effect, and after the Chinese torreya oil and the flaxseed oil are compounded, the blood fat metabolism can be effectively regulated, the total cholesterol level can be reduced, and the content of high-density lipoprotein cholesterol can be increased; the Chinese torreya oil is extracted through a low-temperature pressing process, the linseed oil is prepared through a cold pressing process, active components in the raw materials are reserved to the maximum extent, and meanwhile, the stability and uniformity of functional components in the product are ensured by combining a feeding pump filtering process and a rolling die shaping process; by optimizing the formula and the preparation process of the gel matrix, the product has good elasticity and chewing feeling, is convenient to carry and take and is suitable for daily use. The health-care food does not contain artificially synthesized additives, all the raw materials are natural sources, and the health-care food is suitable for patients with hypercholesterolemia and crowds needing to regulate blood fat, and has relatively high safety and market promotion value.

The present disclosure relates to novel therapeutic compounds, known as RNAi agents, that decrease expression of the HMGCR receptor (expressed by the HMGCR gene), thereby decreasing expression of mRNA and protein expression. Such RNAi agents are useful in the treatment of diseases and disorders involving the regulation of HMGCR expression and function, such as diseases and disorders that are risk factors for ASCVD (such as, dyslipidemia, such as hypercholesteremia).

This document describes the crystalline and liquid crystalline forms of sodium 25HC3S. This disclosure includes sodium 25HC3S in forms I, II, III, V, IX, XI, and XIII, and combinations thereof. Pharmaceutical formulations of the said forms or combinations thereof are further disclosed herein, as well as methods for treating or preventing diseases such as hypercholesterolemia, hypertriglyceridemia, and conditions associated with fat accumulation and inflammation (e.g., non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, and atherosclerosis). Methods for preparing 25HC3S are also provided.

The invention relates to oral probiotic hydrogel as well as a preparation method and application thereof. The preparation method comprises the following steps: mixing inulin-modified thiolated polysaccharide with a probiotic liquid, and quickly crosslinking to form probiotic hydrogel, so as to construct a colon-targeted probiotic delivery system; the system can effectively protect the probiotics from passing through the upper digestive tract, and realizes targeted release of the probiotics at the colon part by using a dual mechanism that the inulin is specifically ingested by the probiotics in the colon and the disulfide bond is easily reduced and disassembled by reduced glutathione (GSH) in the colon. The oral probiotic hydrogel disclosed by the invention is applied to preparation of medicines for preventing and treating irritable bowel syndrome, diarrhea, constipation, dyspepsia, inflammatory bowel disease, colon cancer, diabetes mellitus, obesity and hypercholesteremia.

Aspects of the disclosure relate to compositions and methods for multiplexed gene silencing in a cell or subject. In some embodiments, the disclosure provides an isolated nucleic acid or an rAAV encoding a transgene comprising a RNA-guided nuclease (RGN) operably linked to a first promoter, and a second promoter operably linked to a multi guide-RNA (multi-gRNA) expression cassette encoding one or more gRNAs targeting a gene associated with hypercholesterolemia or dyslipidemia. In some embodiments, the disclosure provides methods of treating a subject having hypercholesterolemia or dyslipidemia by administering the compositions.

The present disclosure relates to novel therapeutic compounds referred to as RNAi agents that reduce the expression of HMGCR receptors (expressed by the HMGCR gene), thereby reducing mRNA and protein expression. Such RNAi agents are useful in the treatment of diseases and disorders involving modulation of HMGCR expression and function, such as diseases and disorders that are risk factors of ASCVD (e.g., dyslipidemia, such as hypercholesterolemia).

The present invention relates to methods of treating or preventing cholesterol related disorders, such as hypercholesterolemia, hyperlipidemia or dyslipidemia, using antibodies against proprotein convertase subtilisin / kexin type 9 (PCSK9). Formulations and methods of producing said formulations are also described.

A method of reducing elevated plasma levels of cholesterol in a subject is disclosed. Also disclosed is a method of treating hypercholesterolemia in a subject. The method comprises administering to the subject an effective amount of Compound 1, or a pharmaceutically acceptable salt thereof, in the absence of a cholesterol-lowering drug.

Provided herein are novel thyroid hormone receptor (TR) agonists, e.g., having Formula I, II, or III. Also provided are methods of preparing the novel TR agonists and method of using the novel TR agonists for treating diseases or disorder modulated by TR agonists, such as NAFLD, NASH, diabetes, hyperlipidemia and / or hypercholesterolemia.

This invention relates to a method for treating patients with heterozygous familial hypercholesterolemia (heFH), comprising administering a pharmaceutical composition containing a PCSK9 inhibitor to a patient with heterozygous familial hypercholesterolemia. In some embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody, such as the exemplary antibody referred to herein as mAb316P. The method of the present invention can be used to treat patients with heterozygous familial hypercholesterolemia whose cholesterol is poorly controlled with the maximum tolerated dose of statins, with or without other lipid-lowering therapy.

The invention discloses application of a substance for promoting an IDH3A level in preparation of related products for treating hypercholesterolemia. According to the present invention, the IDH3A overexpression adeno-associated virus 8 (IDH3A-AAV8) is constructed for the first time, and the IDH3A-AAV8 can specifically improve the expression level of the IDH3A gene in the liver so as to effectively reduce the plasma total cholesterol level of the hypercholesterolemia model mouse, improve the liver lipid deposition and finally achieve the effective treatment of the hypercholesterolemia; meanwhile, the correlation between the IDH3A and the hypercholesteremia is disclosed for the first time, and it is proved that the hypercholesteremia can be effectively treated by improving IDH3A gene expression or enhancing IDH3A protein activity.

The invention provides a double-layer tablet containing ezetimibe and fenofibrate. The double-layer tablet comprises an ezetimibe quick release layer and a fenofibrate slow release layer, the ezetimibe quick-release layer comprises ezetimibe, a quick-release layer filler, a quick-release layer surfactant, a quick-release layer adhesive, a quick-release layer disintegrating agent and a quick-release layer lubricant; the fenofibrate sustained-release layer comprises fenofibrate, a sustained-release layer filler, a sustained-release layer disintegrating agent, a sustained-release layer adhesive, a sustained-release layer solubilizer, a sustained-release layer sustained-release framework material and a sustained-release layer lubricant. The invention also provides a preparation method of the double-layer tablet. The double-layer tablet provided by the invention can be used for clinical treatment of hypercholesterolemia, hypertriglyceridemia and mixed dyslipidemia, the levels of triglyceride, total cholesterol and LDL-C are comprehensively reduced, the level of HDL-C is increased, and the occurrence rate of adverse reactions is relatively low.

The present invention relates to the technical field of medicines, and in particular to a composition for lowering blood lipids and cholesterol, a preparation method therefor, and an application thereof. The composition comprises the following components in parts by weight: 200-1000 parts of phytosterol or an analog thereof, 50-500 parts of red yeast rice extract, and 10-500 parts of lycopene. By means of compounding phytosterol or the analog thereof, the red yeast rice extract, and lycopene in the above composition, it was discovered that phytosterol or the analog thereof, the red yeast rice extract, and lycopene have a synergistic effect of lowering blood lipids and cholesterol, can be used to prepare products for lowering blood lipids and cholesterol, and have applications in the preparation of products for the prevention, alleviation, adjunctive treatment, or treatment of hyperlipidemia and / or hypercholesterolemia.

To provide a polypeptide corresponding in sequence homology to an active region of a 40s ribosomal protein S2 ("RPS2") that is beneficial as a therapeutic for oral and iv administration.SOLUTION: Provided is an isolated polypeptide that comprises or consists of a 40s ribosomal protein S2 (RPS2) or a fragment thereof, having a specific amino acid sequence.SELECTED DRAWING: Figure 1

The invention provides an oral pharmaceutical composition containing kidney bean kinase and application thereof.The pharmaceutical composition comprises kidney bean kinase serving as an active component and a pharmaceutically acceptable carrier, the activity of kidney bean kinase is not lower than 2000 U / mg, and the kidney bean kinase up-regulates the LDL-R expression level and promotes LDL uptake and degradation by hydrolyzing PCSK9 protein in liver cells, so that the activity of the kidney bean kinase is improved, and the activity of the kidney bean kinase is improved. The lipid-lowering effect is achieved. The pharmaceutical composition containing the kidney bean kinase can be taken orally, is natural in source and high in safety, can effectively reduce expression of PCSK9 protein, and is used for treating or preventing hypercholesteremia, atherosclerosis and complications thereof.

The invention discloses a parabacteroides gore DZ001 strain with a cholesterol sulfation function and application of the parabacteroides gore DZ001 strain. The preservation number of the parabacteroides gore DZ001 is GDMCC No: 67376, and the preservation number of the parabacteroides gore DZ001 is H. The strain is separated from faeces of healthy people, a genome carries a sequence for coding sulfotransferase, cholesterol can be specifically catalyzed to generate cholesterol sulfate with higher water solubility, intestinal epithelium reabsorption is blocked, and faeces excretion is promoted. In-vitro experiments show that the strain has excellent cholesterol degradation capacity, gastrointestinal tract tolerance and safe gamma-hemolysis characteristics; in-vivo experiments prove that the traditional Chinese medicine composition can remarkably reduce serum total cholesterol and triglyceride levels of high-fat diet mice, increase high-density lipoprotein cholesterol, improve liver fatty degeneration and regulate blood glucose metabolism. The strain and viable bacteria, supernate or cell-free extract thereof can be widely applied to preparation of cholesterol-reducing health-care foods, medicines and animal feeds, and a new way is provided for prevention and treatment of hypercholesterolemia and related cardiovascular and cerebrovascular diseases.

The present invention relates to methods of treating or preventing cholesterol related disorders, such as hypercholesterolemia, hyperlipidemia or dyslipidemia, using antibodies against proprotein convertase subtilisin / kexin type 9 (PCSK9). Formulations and methods of producing said formulations are also described.

The present disclosure relates to methods of treating, preventing, or managing a cardiovascular and / or metabolic disorder in a human subject in need thereof by administering a human FGF21 protein variant, wherein the metabolic and / or cardiovascular disorder is selected from hypercholesterolemia, dyslipidemia, hypertriglyceridemia, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes, and obesity.